Across
- 2. which DNA repair enzyme family is pharmacologically inhibited to exploit synthetic lethality in BRCA1/2-deficient tumors?
- 6. long non-coding RNA that inhibits CyclinD-CDK complex
- 8. treatment given before main treatment (usually before surgery)
- 11. TNM system
- 12. give shape to cell
- 13. growth of new blood vessels to supply a tumor
- 14. mutation that is the first driver breaks key point of cell control/survival
Down
- 1. spreading of cancer
- 3. backup systems to make tumors resilient
- 4. family balancing apoptosis
- 5. targets dihydrofolate reductase (DHFR)
- 7. non-cancerous
- 9. abnormal mass of tissue
- 10. localized hypermutation clusters (often APOBEC enzymes)
- 12. platinum based cancer chemotherapy